

18 **1 Keywords**

19 vaccine allocation, vaccine distribution, emerging pathogen, pandemics

20

21 **2 Abstract**

22 Vaccine allocation decisions during emerging pandemics have proven to be challenging due to
23 competing ethical, practical, and political considerations. Complicating decision making, policy
24 makers need to consider vaccine allocation strategies that balance needs both within and between
25 populations. Due to limited vaccine stockpiles, vaccine doses should be allocated in locations where
26 their impact will be maximized. Using a susceptible-exposed-infectious-recovered (SEIR) model we
27 examine optimal vaccine allocation decisions across two populations considering the impact of
28 population size, underlying immunity, continuous vaccine roll-out, heterogeneous population risk
29 structure, and differences in disease transmissibility. We find that in the context of an emerging
30 pathogen where many epidemiologic characteristics might not be known, equal vaccine allocation
31 between populations performs optimally in most scenarios. In the specific case considering
32 heterogeneous population risk structure, first targeting individuals at higher risk of transmission or
33 death due to infection leads to equal resource allocation across populations.

34

35 **3 Introduction**

36 In the past two decades, the 2009 H1N1 influenza pandemic and the recent 2019 SARS-CoV-2
37 pandemic have highlighted the need for control and mitigation measures against emerging
38 pathogens. SARS-CoV-2 has caused considerable morbidity and mortality, resulting in over 542
39 million cases and 6.3 million deaths worldwide as of June 2022 (Dong et al., 2020). Previously, the
40 2009 Swine flu pandemic was estimated to have caused around 200 thousand deaths in the first
41 twelve months globally (Dawood et al., 2012; Simonsen et al., 2013). Vaccines are currently the most
42 effective public health intervention available against emerging pathogens, and have greatly reduced
43 severe disease outcomes (Watson et al., 2022).

44

45 Even with the approval and availability of vaccines, both the H1N1 and SARS-CoV-2 pandemics have
46 highlighted key challenges in in the roll-out and uptake of vaccines globally during an ongoing
47 epidemic. During the 2009 H1N1 influenza pandemic, global influenza A vaccine supply was much
48 lower than initially estimated, resulting in large inequities in vaccine access across countries (Fidler,
49 2010; Kaiser Family Foundation, 2009). In the aftermath of the 2009 H1N1 influenza pandemic the
50 World health Organization (WHO) developed a preparedness framework for the sharing of vaccines
51 in a timely manner, and encouraged advance agreements for vaccine allocation and delivery to
52 improve pandemic response globally (Fineberg, 2014; World Health Organization, 2011).

53

54 The COVID-19 pandemic has seen similar challenges, with vaccine supply falling far short of demand.
55 Even with the approval of multiple vaccines, distributed across different regions globally, roll-out has
56 been slow, with vaccination rates highly unequal across countries (Mathieu et al., 2021; Rydland et
57 al., 2022). At the end of 2021, some countries had already vaccinated over 90% of their population,
58 while others did not have access to vaccines (Mathieu et al., 2021). Overall, at the beginning of
59 emerging pandemics, vaccination allocation decisions have been made under the constraint of a
60 limited vaccine stockpile and multiple factors need to be considered to maximize the effect of each
61 dose both within and across populations.

62

63 Across both pandemics, numerous papers have shown targeting specific subgroups within the
64 population can result in decreased disease-related morbidity and mortality. For 2009 H1N1
65 influenza, models found prioritizing individuals at highest risk of complications resulted in the lowest
66 morbidity and mortality (Chowell et al., 2009; Lee et al., 2010; Tuite et al., 2010). For the 2019 SARS-

67 CoV-2 pandemic, previous work (Bubar et al., 2021; Hogan et al., 2020; Matrajt et al., 2021) has
68 shown, targeting specific subgroups within a given population, including older individuals, results in
69 decreased COVID-19 morbidity and mortality. Other papers looking at health and occupational risk
70 factors (Buckner et al., 2021; Islam et al., 2021) found prioritizing certain occupational groups
71 including healthcare workers, and other essential workers also decreased COVID-19 morbidity and
72 mortality. However, previous theoretical work (Keeling & Shattock, 2012) has also shown that
73 unequal vaccine allocations might be favorable in emerging infectious disease settings, but are less
74 optimal when incorporating realistic assumptions about population heterogeneity and contact
75 structure. This leaves a potentially conflicting message for policy makers when considering optimal
76 allocation strategies. We build upon this work, by not only considering the optimal decision, but also
77 how the decision compares to all possible allocations across two populations. Illustrating these
78 tradeoffs with a simplified model of an emerging pathogen similar to H1N1 or SARS-CoV-2, our
79 results show that the efficiency gains for unequal allocations that are found in models with highly
80 simplified epidemics are typically small; moreover, they vanish and can even reverse under settings
81 more relevant to pandemics caused by emerging pathogens. Similar to previous findings, we show in
82 more realistic scenarios, incorporating population heterogeneity and interaction between
83 populations, that equal distributions are not only optimal, but vastly outperform unequal
84 distributions.

85

86 **4 Materials & Methods**

87 We use a deterministic, two-population, susceptible-exposed-infectious-recovered (SEIR)
88 compartmental model. We assume people are initially susceptible (S). Susceptible individuals move
89 to the exposed state (E) after an effective contact with an infectious individual. After a latent period,
90 exposed individuals become infectious (I). After the infectious period has elapsed, infectious
91 individuals move to a recovered state (R). We do not account for waning immunity and assume once
92 individuals have recovered, they stay immune to infection for the duration of our simulation, here
93 modeled as three years. We start by assuming that there is no interaction between the two
94 populations, so all disease transitions happen in parallel between the two populations.

95

96 We extend this SEIR model to allow for underlying immunity (Figure 3, S9) and vaccination (all
97 Figures). At the start of the epidemic, in each population, individuals can be in the susceptible (S),
98 infectious (I), or recovered (R) compartments. When there is underlying immunity, a set proportion
99 of individuals are placed in R. Individuals in R, whether through underlying immunity or infection
100 through the course of the simulation, can never be re-infected. When vaccine doses are distributed
101 to the population, vaccinated individuals are placed in R if the vaccination is successful. We assume
102 that the vaccine is all-or-nothing with 95% efficacy, meaning 95% of those who are vaccinated are
103 placed in R and the remainder stay in S. When there is underlying immunity and vaccination, immune
104 individuals may be vaccinated; vaccination has no effect on them, and they remain in R. Finally, we
105 initialize each simulation by placing 0.1% of individuals in I and allow the epidemic to run,
106 unmitigated except by vaccination, through each population. Full model parameters and equations
107 are shown in SI Appendix A.2. Where possible, parameters represent estimates from both the 2009
108 H1N1 influenza pandemic and the 2019 SARS-CoV-2 pandemic; for example, 95% vaccine efficacy is
109 close to that estimated for the Moderna mRNA vaccine Spikevax (Doria-Rose et al., 2021).

110

111 To recreate the results of Keeling and Shattock (Keeling & Shattock, 2012) we model two
112 homogeneous populations with identical characteristics apart from population size. In this scenario
113 we assume population 2 is double the size of population 1 (Figure 2). For later scenarios, which
114 consider the impact of heterogeneity within populations, we simulate two populations that are
115 identical in size, but vary in their population characteristics (e.g., fraction high risk) (Figure 5, S3-S7).

116

117 Next, we extend the model by allowing for heterogeneous risk groups. First, within each population,
118 we model efficient transmitters of infection, for example young adults or children (Goldstein et al.,
119 2021; Kissler et al., 2020) (Figure 5, S3, S4, S6). In this scenario, we assume high-transmitters are
120 four times more likely to transmit compared to low transmitters (Monod et al., 2021). We fix the
121 within-population structure to allow the global R_0 to equal 2, 4, 8 or 16. The full derivation is shown
122 in SI Appendix A.2.6. The SEIR model equation are in SI Appendix A.2.4.

123
124 Second, we instead model individuals at elevated risk of death from infection (Figure 5, S3, S5, S7).
125 For COVID-19 this can represent, for example, elderly individuals or other individuals with co-
126 morbidities known to exacerbate disease (C. Wu et al., 2020; Zhou et al., 2020). For the 2009 H1N1
127 influenza pandemic, this represents young adults. For simplicity of the model, we assume these
128 individuals are five times more likely to die than other infected individuals (Lee et al., 2010; Presanis
129 et al., 2009; Williamson et al., 2020). Note that infection fatality rates are assumed to be constant
130 throughout the epidemic, which may not be realistic as health care resources are strained by large
131 caseloads or case management improves over time. The SEIR model equations are in SI Appendix
132 A.2.5.

133
134 Similar to the homogeneous two-population scenario described above, we initialize the model by
135 placing individuals from each population in the susceptible or recovered state based on the pre-
136 existing immunity level and the vaccine allocation scenario. The total number of vaccine doses are
137 split amongst the two populations based on the scenario. Within each population, high-risk
138 individuals are vaccinated first, with leftover doses then allocated to the low-risk population, as
139 described in SI Appendix A.2.7.

140
141 Finally, we model the scenario where vaccines are unavailable at the start of the epidemic but are
142 progressively rolled out over the course of the epidemic (Figure 4, S4-S7). For this simulation we vary
143 both the timing of roll-out, and the fraction of the population vaccinated each day. We allow vaccine
144 roll-out to start 1, 10, 30, 50, or 100 days after the epidemic has begun and vary the proportion of the
145 population vaccinated from 1% to 3% per day. For these simulations, the vaccine is allocated within
146 and across populations identically to the scenarios described above for the homogeneous and
147 heterogeneous scenarios.

148
149 For each simulation we calculate the cumulative number of infections and deaths from the
150 deterministic SEIR model at the end of the epidemic. Across each scenario we define the optimal
151 allocation strategy as the one that minimizes the total epidemic size (cumulative number of
152 infections) across both populations. Within the high morbidity scenario, we define the optimal
153 allocation strategy as the one that minimizes the total number of deaths across both populations. This
154 is equivalent to maximizing the total number of people across both populations that escape infection
155 (or death) (Duijzer et al., 2018).

156
157 We conduct sensitivity analyses to assess the robustness of our results. First, we model a leaky
158 vaccine scenario where we assume the vaccine reduces susceptibility to infection for each individual
159 by 95% (Figure S1). As a result, all vaccinated individuals (except those previously immune through
160 natural infection) can become infected with the virus, although the probability of infection for each
161 contact with an infected individual is lower than for an unvaccinated individual. The SEIR model
162 equations are in SI Appendix A.2.3. We further extend the model by relaxing the assumption that the
163 two populations do not interact (Figure S2). We allow a fraction i of infected individuals in both
164 populations to contribute to the force of infection in the other population instead of their own
165 population. An i value of 0 corresponds to no interaction, and an i value of 0.5 corresponds to
166 complete interaction between the two populations (i.e. is equivalent to one large population). Next,

167 for each of the scenarios above, we additionally consider the impact of varying R_0 between 2 and 16,
168 allowing for improved understanding across a variety of pathogens or viral variants (McMorrow,
169 2021) (Figure). Finally, we relax the assumption of 95% vaccine efficacy by modelling a range of
170 values from 50% to 90% (Figure S8, S9). Full model equations are shown in SI Appendix A.2.
171 All analyses were conducted in R version 4.0.3.

172

173 **5 Results**

174

175 **5.1 Literature review**

176 We reviewed the literature on optimal vaccine allocation across populations that was published prior
177 to the emergence of SARS-CoV-2 (see SI Table A.3.1). Multiple papers (Forster & Gilligan, 2007;
178 Keeling & Shattock, 2012; Klepac et al., 2011; Rowthorn et al., 2009; J. T. Wu et al., 2007) have shown
179 that allocation proportional to population size is rarely optimal. Further, previous studies have
180 highlighted that the timing of vaccine allocation (Matrajt & Longini, 2010; Mylius et al., 2008;
181 Teytelman & Larson, 2013), heterogeneity in population composition, as well as the stochasticity in
182 infection dynamics affect the optimal distribution (Nguyen & Carlson, 2016; Yuan et al., 2015).
183 Duijzer et al. (Duijzer et al., 2018) provide important contributions by showing that the optimal
184 vaccination threshold is often not the herd immunity threshold as further detailed in SI Appendix
185 A.3.2.

186


187 **5.2 Optimal allocation in two populations of equal size**

188 We build upon the existing literature by first examining allocation decisions in the simple scenario of
189 two identical, non-interacting populations with no underlying immune protection to the pathogen
190 (see Figure 1). In the simplest case, with a small number of vaccine doses available, pro-rata
191 allocation performs comparably to highly unequal allocation strategies. As the number of vaccine
192 doses increases, highly unequal strategies gain advantage over pro-rata allocation. This occurs
193 because one population can be vaccinated close to, but lower than, its herd immunity threshold,
194 maximizing the indirect effect of the vaccine doses (Duijzer et al., 2018). When sufficient vaccines are
195 available for both populations to reach that threshold, more unequal strategies use the doses less
196 efficiently, as indicated by the increasing arms of the “W” shapes in Figure 1. Allocating doses to the
197 population that has reached its threshold provides limited benefit in that population and withholds
198 doses from the other. When there are nearly enough doses to reach the thresholds in both
199 populations, the optimal strategy becomes equal allocation between the two populations.

200

201 As the basic reproductive number increases, we again see that unequal allocations perform optimally,
202 as the number of available doses is less than the number needed to reach the critical herd immunity
203 threshold in both populations. In these scenarios, vaccinating one or the other population until it can
204 reach the critical herd immunity threshold results in the lowest cumulative cases across both
205 populations. At very high basic reproductive numbers (i.e., $R_0 = 16$), pro-rata allocation performs
206 comparably to highly unequal allocation strategies.

207



208
209
210
211
212
213
214
215
216
217

Figure 1: Performance of different allocation strategies of a limited vaccine stockpile across two homogeneous population of equal size with no underlying immunity and prophylactic vaccination. Both populations have one million individuals. Each color represents a different number of total vaccine doses. Each line represents a different basic reproductive number. Each curve shows the cumulative number of cases across both population 1 and 2 for different proportions of doses given each population. Across each curve, from left to right, the proportion of doses to population 1 goes from 0 to 100%. Conversely, for population 2, the proportion of doses goes from 100% to 0%.

218 **5.3 Optimal allocation in two populations of unequal size**


219 Extending the simple case of non-interacting populations of equal size, previous studies have shown
220 how optimal allocation across populations of different sizes is not linear, but varies with the number
221 of doses available in a characteristic, and often counter-intuitive, “switching” pattern (Duijzer et al.,
222 2018; Keeling & Shattock, 2012; Klepac et al., 2011).

223
224 As shown in Figure 2 (top), when the number of doses available is very limited, optimal allocation
225 concentrates all vaccine doses to the smallest population, not assigning any to the largest population
226 (regime 1). As the number of doses allocated to the smaller population reaches its threshold,
227 additional doses are gradually allocated to the larger population (regime 2). Strikingly, a drastic
228 switch happens between regimes 2 and 3, and in regime 3 all doses are allocated to the larger
229 population and none to the smaller one. Then, as the largest population itself reaches its threshold,
230 supplementary doses are assigned to the smaller population (regime 4). When the number of
231 vaccines available allows both populations to attain their respective thresholds, vaccines are
232 allocated proportionally to the population sizes (regime 5). Note that here we assume that the total
233 number of doses is fixed at the time of allocation and no additional doses become available over time.
234 We relax this assumption in later scenarios considering continuous rollout.

235
236 For most values of vaccine available, the optimal allocation is highly unequal (regime 1, 2, 3, 4), as
237 previously shown (Duijzer et al., 2018; Keeling & Shattock, 2012). This counterintuitive result is
238 caused by the non-linearity of the indirect effect from each additional vaccine dose. Additional doses
239 are allocated to the population where they have the largest benefit. For example, in regime 1 of Figure
240 2, additional doses bring a larger benefit in the smaller population than they would in the larger
241 population.

242
243 Importantly, while prior literature (Keeling & Shattock, 2012) demonstrates that unequal allocations
244 can be optimal, these results show that the benefit of such unequal, optimal allocations over more
245 nearly equal ones is often small. As shown in Figure 2 (bottom), for low numbers of vaccine doses
246 (regimes 1 and 2), although concentrating all doses to the smallest population is optimal, other
247 strategies do not perform much worse. Each regime is characterized by a different allocation profile
248 that gives rise to a different optimum, indicated by black points. In regime 4, the characteristic W
249 shape appears where a fully unequal allocation is sub-optimal, regardless of which population is
250 vaccinated.

251



252
253
254
255
256
257
258
259
260
261
262
263

Figure 2: Top: Optimal allocation strategies of a limited vaccine stockpile across two homogeneous populations of unequal size with no underlying immunity, prophylactic vaccination and an R_0 of 2. Populations 1 (blue) and 2 (red) have one and two million individuals, respectively. Dashed vertical lines were added to highlight regimes (1 to 5) showing different vaccine allocation patterns. Bottom: Performance of allocation strategies for five different numbers of vaccine doses, representative of the regimes shown in the top half of the Figure. Color coding corresponds to vaccine allocation ranging from giving all doses to population 2 (red) to giving all doses to population 1 (blue). The optimal allocation, the minimal value on each plot, is highlighted by a black point.


264 **5.4 Impact of underlying immunity**

265 As vaccines become available to different locations at different points in their local epidemic,
266 populations will have varying degrees of underlying immunity to the virus due to prior infections.
267 Serological surveys estimate that at the end of 2020, around a fifth of the population had already been
268 infected in areas hardest hit during the spring of 2020 (23% in NYC (Rosenberg et al., 2020), 18% in
269 London (Public Health England, 2020) and 11% in Madrid and Paris (Pollán et al., 2020; Salje et al.,
270 2020)). More recent estimates show seroprevalence increased to almost 60% after the Omicron
271 variant became predominant in the United States (Clarke et al., 2022). Select high-risk groups,
272 including health care workers and nursing home residents, have been shown to have an even higher
273 prevalence of SARS-CoV-2 antibodies (Ladhani et al., 2020). To account for underlying immunity, we
274 further simulate optimal allocation decisions with varying levels of underlying immunity in each
275 population to mirror the fact that allocation decisions are made during an ongoing pandemic.

276
277 Comparing two populations with varying amounts of underlying immunity, the optimal strategy
278 favors prioritizing the population that is closer to their herd immunity threshold (Figure 3). Figure 3
279 shows optimal allocation decisions across two homogeneous populations of equal size with no
280 immunity (top left, repeating Figure 1) or increasing degrees of immunity in population 1. With
281 increasing immunity in population 1, the characteristic V- or W-shape becomes more lopsided as
282 fewer doses are required in population 1 to reach the threshold at which doses should be split
283 between populations. Extremely unequal allocation strategies either waste doses or fail to minimize
284 the cumulative number of infections in both populations if given completely to population 1 or 2,
285 respectively. In addition, allocating vaccines to population 1 beyond the amount needed to reach its
286 threshold results in the highest cumulative number of cases because it confers little additional benefit
287 in population 1, and deprives population 2 of vaccines needed to mitigate cases. As before, once the
288 number of doses is large enough to approach or reach the threshold in both populations, optimal
289 strategies move closer to pro-rata allocations.

290
291 As we vary the basic reproductive number, holding vaccine doses fixed, we find the characteristic V
292 and W shapes are shifted to the left. The number of vaccine doses needed to reach the critical herd
293 immunity threshold increases as the basic reproductive number increases. Unequal approaches
294 become more favorable as the level of underlying immunity in population 1 increases, because fewer
295 doses are required for population 1 to reach their herd immunity threshold. Thus, even for very high
296 R_0 values, the optimal strategy, minimizing the cumulative number of cases across both populations,
297 prioritizes allocating doses to the population that is closest to reaching its critical herd immunity
298 threshold.

299



300
 301
 302 **Figure 3:** Performance of different allocation strategies of a limited vaccine stockpile across two
 303 homogeneous populations of equal size (one million individuals) with different underlying immunity,
 304 and prophylactic vaccination. We fix population 2 to have no underlying pathogen immunity and vary
 305 underlying immunity in population 1 from 0 to 40%. Each color represents a different number of
 306 total vaccine doses. Each line represents a different basic reproductive number. The panel on the top
 307 left is equivalent to Figure 1.
 308
 309


310 **5.5 Impact of delayed vaccine roll-out in a homogeneous population**

311 Next, we examine the impact of vaccine roll-out over the course of the epidemic. We find both the
312 timing and speed of roll-out play an important role in minimizing the final size of the epidemic. As
313 shown in Figure 4, the cumulative number of cases across both populations is minimized when
314 vaccine roll-out occurs as soon as possible after the start of the epidemic. Further, the final size is
315 minimized when roll-out speed is increased, vaccinating a larger proportion of the population each
316 day.

317
318 For the early and efficient roll-out (beginning 10 days after the start of the epidemic, at a rate of 2 or
319 3% of the population/day), the vaccination performance profile across possible allocations looks
320 similar to that of the prophylactic vaccine deployment strategy shown in Figure 1. However, for a
321 slower or more delayed roll-out we see highly unequal approaches perform poorly across almost all
322 doses and more equal approaches result in the smallest final size. This is because a larger fraction of
323 the population is naturally infected, minimizing the gains from concentrating vaccine doses in one
324 population.

325
326 As we incorporate differences in transmissibility, we find timing and speed to be of greater
327 importance. Even with a vaccine roll-out 50 days after the start of the epidemic, there are no
328 differences in final size across all allocation strategies, within a given R_0 level, as the epidemic has
329 ended in the population before vaccines are introduced. For higher reproductive numbers, faster,
330 earlier roll-outs are needed for vaccination to have an impact on the total number of infections.

331



332
 333
 334 **Figure 4:** Performance of different allocation strategies of a limited vaccine stockpile across two
 335 homogeneous populations of equal size (one million individuals) with no underlying immunity, with
 336 vaccines rolled out at different speeds and different times after the start of the epidemic. Each color
 337 represents a different number of total vaccine doses. Each line represents a different basic
 338 reproductive number. We vary both the timing and speed of roll-out between 10, 50 or 100 days
 339 after the start of the epidemic with 1, 2, or 3% of the population vaccinated per day. Each column
 340 represents a given roll-out speed while each row represents a different timing.
 341


342 **5.6 Impact of heterogeneous population structure**

343 Looking within a population, many studies have shown optimal strategies favor prioritizing older
344 individuals (e.g., those aged 60 or over) or those with certain comorbidities when the goal is
345 minimizing mortality. If the goal instead is minimizing final size, targeting adults 20-49 with an
346 effective transmission-blocking vaccine minimizes cumulative incidence (Bubar et al., 2021; Matrajt
347 et al., 2021). Here we model the impact of heterogeneous population structure to examine the impact
348 of strategies across populations. These simulations consider populations with heterogeneous
349 transmission or with heterogeneous risk of death.

350
351 Targeting high transmission or high mortality groups first within a population shifts the optimal
352 allocation across the two populations towards pro-rata allocation (Figure 5, S3). In Figure 5 we first
353 model the impact of prophylactic vaccination in a heterogeneous population structure with 25% of
354 each population at either high risk of transmission (top) or death (bottom). In the high-transmission
355 scenario, the behavior looks similar to that in Figure 1 for a low number of doses, representing the
356 trade-off between vaccinating the high-transmitters in both populations. Once there are enough
357 doses available to vaccinate enough high-transmitters to reduce transmission dramatically, the
358 optimal strategy favors more pro-rata allocations across the two populations as high-transmitters
359 are driving the bulk of transmission. This shift to more equal allocations occurs at a lower number of
360 vaccine doses compared to Figure 1. In the high-mortality scenario, we see the optimal allocation
361 rapidly shift to pro-rata strategies, starting at a very low number of vaccine doses. Interestingly, the
362 sequence of profiles from Figure 1 is repeated twice. First, for a low number of vaccine doses there is
363 a trade-off between vaccinating the high-mortality individuals in both populations. Then for higher
364 vaccine counts the trade-off is repeated, this time between all individuals of both populations. While
365 this trade-off exists, pro-rata allocation is heavily favored across almost all levels of available vaccine
366 doses.

367
368 Looking across different levels of R_0 , we find similar trends. Vaccinating higher transmission or
369 mortality groups first results in more equal allocation strategies across populations. For higher R_0
370 values (i.e., 8 or 16) pro-rata allocation performs comparably to highly unequal strategies. Increasing
371 the proportion of high-risk individuals to 50% of the population (Figure S3) we find similar trends
372 for R_0 values of 2 and 4. For higher R_0 values, unequal approaches perform optimally as a larger
373 fraction of the population is driving transmission, so effectively targeting this group in either
374 population minimizes the cumulative number of deaths or cases across the two populations.

375
376 Next, we considered the impact of continuous roll-out for both the high transmission and high
377 mortality scenarios. We find that across both high-risk scenarios and all vaccine roll-out times and
378 speeds, unequal allocation is highly sub-optimal (Figure S4-S7). Similarly to Figure 4, we vary the
379 start date of vaccination roll-out (1, 10, 30, 50, or 100 days), the daily vaccination rate (1, 2 or 3%
380 per day), and the proportion of the population at high risk (25 or 50%). We find that both the speed
381 and timing of vaccine roll-out are important factors in minimizing the cumulative number of cases or
382 deaths across the two populations and see the greatest reduction in cumulative deaths and final size
383 with the earliest and fastest roll-out. Specifically, for vaccine stockpiles larger than 500,000 doses,
384 the achievable impact of vaccination is more dependent on the timing (solid vs. dashed curves) and
385 speed (different panels) of vaccine roll-out rather than on the total number of doses available.



386
 387 **Figure 5:** Performance of different allocation strategies of a limited vaccine stockpile across two
 388 heterogeneous populations of equal size (one million individuals) with no underlying immunity and
 389 prophylactic vaccination. Each color represents a different number of total vaccine doses. Each line
 390 represents a different basic reproductive number. In both the high transmission scenario (top) and
 391 high mortality scenario (bottom), 25% of both populations are high risk.
 392

393 5.7 Sensitivity Analyses

394 We assessed the robustness of our results by varying the characteristics of the vaccine and
395 connection between populations to be more representative of the current pandemic. As expected,
396 the leaky and all-or-nothing vaccine have the same critical vaccination threshold, though the
397 cumulative number of cases in the leaky vaccine scenario is equal to or larger than the all-or-
398 nothing scenario (Magpantay et al., 2014) (Figure S1).

399
400 In the previous situations we have only considered the scenario of non-interacting populations. As
401 we relax this strict assumption, we find that as the amount of interaction between the two
402 populations increases, equal strategies are most favorable (Figure S2). When the force of infection
403 in each population depends on epidemic dynamics in both populations, accounting for interaction
404 drastically changes the optimal allocation profiles and favors equal allocation between populations,
405 as seen in previous work (Duijzer et al., 2018; Keeling & Shattock, 2012). Even for low values of the
406 interaction parameter i , equal allocation rapidly becomes optimal. Indeed, for i values higher than
407 0.01 — which corresponds to one out of every hundred infected individuals contributing to
408 infection in the other population — equal allocation between the two population always performs
409 best. As i further increases, unequal strategies progressively approach the optimal (equal)
410 allocation as indicated by the flattening of the curves. For i equal to 0.5, when the two populations
411 concretely behave like one large population, all allocation strategies perform almost identically.
412 Compared to the non-interacting case, allowing for interaction between the two populations leads
413 to a higher cumulative number of infections for all possible vaccine allocation strategies, and the
414 “W”-shaped allocation curve no longer appears.

415
416 As we increase the basic reproductive number, we find that the optimal strategy quickly favors
417 more equal allocation decisions. In addition, interaction between the two populations becomes less
418 important for very high values of R_0 , as the allocation profiles look similar across all interaction
419 parameters for R_0 values of 8 and 16.

420
421 As vaccine efficacy decreases from 90% to 50%, the cumulative number of cases across both
422 populations increases, the critical herd immunity threshold increases and equal-allocation
423 strategies become less favorable, with unequal allocations being optimal in some cases for the
424 lowest efficacy values. Even for these situations, however, the advantage of unequal allocations are
425 modest (Figure S8). Next, as we increase immunity levels across both populations, the total number
426 of cases is reduced, and the critical herd immunity threshold is lowered. Even with low vaccine
427 efficacy values, in scenarios with high underlying immunity, the critical herd immunity threshold
428 can be reached, and equal allocations are favored (Figure S9).

431 6 Discussion

432 In emerging pandemics, countries must make challenging vaccine allocation decisions due to
433 resource constraints. Previous studies (Keeling & Shattock, 2012) have shown simple scenarios favor
434 unequal allocation. We recreated those findings, and further extend vaccine allocation theory, and
435 apply it to scenarios similar to the 2019 SARS-CoV-2 and 2009 H1N1 influenza pandemics. We focus
436 on these emerging pathogens as those pandemics are the ones for which we have the greatest amount
437 of data, understanding, and for which vaccines were deployed while the pandemic was ongoing.

438
439 In the simple case of two non-interacting populations of identical size we show that for very high
440 quantities of vaccine, relative to population size, equal allocation strategies are optimal. For very few
441 doses, all strategies provide comparable results. This supports the European Commission’s decision

442 to allocate vaccine doses proportional to population size among the 27 European Nations (European
443 Commission, 2020). In this simplest model, until there is enough vaccine for both populations to
444 approach their critical herd immunity threshold, optimal strategies favor a highly unequal approach,
445 allocating doses to either population 1 or 2 until the population has reached its threshold. If the
446 populations vary in size, allocation decisions vary, and as the number of vaccines increases, focus
447 switches from the smaller population to the larger one, as supported by Keeling and Shattock
448 (Keeling & Shattock, 2012).

449
450 We consider more realistic scenarios that better mirror the diversity and complexities of emerging
451 pandemics including underlying immunity, population interaction, continuous vaccine roll-out,
452 heterogeneous population structure, and differences in underlying disease transmissibility (either
453 because of biological or social factors). While many of these parameters are either unknown or
454 changing throughout the course of the epidemic, we find that, across a range of scenarios, optimal
455 allocation decisions often favor equal allocation across populations. Since these strategies are often
456 optimal or nearly optimal across a range of parameters, while unequal allocations are only generally
457 optimal for narrow parameter ranges, more pro-rata strategies might be the best option under
458 uncertainty in an ongoing epidemic. Moreover, during an emerging pandemic, it may be unclear
459 whether the newly developed vaccines confer protection against transmission, thus limiting the
460 potential benefit from unequal vaccine allocation strategies that rely on maximizing the benefit from
461 indirect protection in one population. It may thus be preferable to focus on equal allocation strategies
462 as those rely more on the direct protection against disease. Parameter values from COVID-19 and
463 pandemic influenza illustrate this phenomenon; however, these results contribute more generally to
464 the existing vaccine allocation theory for any epidemic emerging in multiple populations when key
465 epidemic variables remain unknown.

466
467 For scenarios considering heterogeneous population risk, we find that first targeting high risk
468 individuals, either high-transmitters or those at higher risk of death after infection, results in more
469 equal allocations between populations being optimal. Targeting high-risk individuals first, then
470 shifting priority to lower-risk individuals is supported by previous modeling work, looking at SARS-
471 CoV-2 vaccine allocations within a single population (Bubar et al., 2021; Chen et al., 2020; Hogan et
472 al., 2020; Matrajt et al., 2021; Moore et al., 2021), and is in concordance with the ongoing COVAX
473 strategy, targeting early doses to high-risk individuals, and the USA's implement which vaccinated
474 health care workers and elderly individuals first (Gayle et al., 2020; World Health Organization,
475 2020). This also supports previous guidelines for 2009 H1N1 influenza where vaccines were targeted
476 at high risk groups first, before shifting to the general population (Centers for Disease Control and
477 Prevention, 2009).

478
479 Our modeling analyses are subject to many simplifying assumptions on population dynamics and
480 vaccine characteristics that may not be applicable to the current pandemic. We consider a vaccine
481 that prevents both disease and infection, thus providing indirect protection to a fraction of the
482 population. While some vaccines are able to reduce infectiousness, in future pandemics this effect
483 will still need to be precisely assessed. We do not model vaccine refusal and assume that all
484 individuals given doses accept them. Recent studies (Dror et al., 2020) show vaccine hesitancy as a
485 threat to successful pandemic response. Next, we do not consider delays between doses, but model
486 the epidemic from a final dose which confers 95% efficacy. Due to vaccine shortages, the delay
487 between the first and second dose could impact our findings as individuals may be able to get infected
488 in the interim. Further, we only model one available vaccine. The current SARS-CoV-2 pandemic
489 illustrates how the vaccine landscape can be complex, as multiple vaccines are available, with many
490 more rapidly undergoing testing. Considerations for optimal allocation in this context are more
491 complicated, especially if the vaccines have different immunogenicity profiles, and the quantity of

492 doses and timing of roll-out varies across candidates. Finally, we do not consider the impact of non-
493 pharmaceutical interventions (NPIs) in conjunction with vaccination.

494
495 Furthermore, we only model allocation strategies within two symmetric populations. It is likely that
496 policy makers will face allocation decisions across multiple countries, or across multiple regions
497 within a country. While our analyses do not extend to more than two locations, general principles
498 should remain the same, as illustrated elsewhere for three populations (Keeling & Shattock,
499 2012).(Duijzer et al., 2018).

500
501 Future modeling work on vaccination strategies during emerging pandemics is needed, for example
502 considering scenarios where multiple vaccine candidates are rolled out simultaneously. These
503 studies should also consider the effects of vaccines on reducing hospitalizations and preserving
504 hospital capacity, which may have indirect benefits for mortality rates for COVID-19 and other
505 diseases beyond the direct prevention of infection in high-risk populations. In addition, other work
506 should also consider populations with varying epidemic dynamics, and distribution capacity. Indeed,
507 it has been argued that populations at higher immediate risk of disease spread and populations
508 where vaccine roll-out is most efficient should be prioritized for vaccine allocation (Emanuel &
509 Persad, 2021).

510
511 With vaccine supplies usually severely constrained, in the future rapid allocation decisions will need
512 to be made while the pandemic is ongoing. Due to the global impact and magnitude of some
513 pandemics such as the current 2019 SARS-CoV-2 pandemic, further political and economic
514 constraints will likely play a large role in allocation decisions. Mathematical modelling can provide
515 insight into optimal allocation strategies that maximize the benefit from each dose. Conclusions from
516 such models should be balanced with ethical considerations on the fairness of allocation that also
517 minimize disparities in access. We show key principles that should be considered in the design of
518 realistic and implementable allocation strategies.

519

520 **7 Acknowledgments**

521 We thank Dr. Kendall Hoyt for helpful discussions.

522

523 **8 Funding & Competing Interest**

524 ER, LKS and ML were supported by the Morris-Singer Fund. KJ was supported by NIH Training Grant
525 2T32AI007535. This work was supported in part by Award Number U01CA261277 from the US
526 National Cancer Institute of the National Institutes of Health. The content of this article is solely the
527 responsibility of the authors and does not necessarily represent the official views of the Morris-
528 Singer Fund or the National Institutes of Health.

529
530 Eva Rumpler, Lee Kennedy-Shaffer, and Rafia Bosan have no conflicts of interest to disclose. Keya
531 Joshi reports a paid summer internship with Janssen Pharmaceuticals for work unrelated to COVID-
532 19. Marc Lipsitch reports grants from CDC, grants from NIH, grants from UK NIHR, grants from Pfizer,
533 personal fees from Merck, personal fees from Janssen, personal fees from Sanofi Pasteur, personal
534 fees from Bristol Myers Squibb, personal fees from Peter Diamandis/Abundance Platinum, outside
535 the submitted work; and Unpaid advice to One Day Sooner, Pfizer, Janssen, Astra-Zeneca, COVAX
536 (United Biomedical).

537 **References**

- 538 Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B. (2021).
539 Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science*,
540 371(6532), 916–921. <https://doi.org/10.1126/science.abe6959>
- 541 Buckner, J. H., Chowell, G., & Springborn, M. R. (2021). Dynamic prioritization of COVID-19 vaccines
542 when social distancing is limited for essential workers. *Proceedings of the National Academy of*
543 *Sciences*, 118(16). <https://doi.org/10.1073/pnas.2025786118>
- 544 Centers for Disease Control and Prevention. (2009). *2009 H1N1 Vaccine Recommendations*.
545 <https://www.cdc.gov/h1n1flu/vaccination/acip.htm>
- 546 Chen, X., Li, M., Simchi-Levi, D., & Zhao, T. (2020). Allocation of COVID-19 Vaccines Under Limited
547 Supply. *MedRxiv*, 2020.08.23.20179820. <https://doi.org/10.1101/2020.08.23.20179820>
- 548 Chowell, G., Viboud, C., Wang, X., Bertozzi, S. M., & Miller, M. A. (2009). Adaptive Vaccination Strategies
549 to Mitigate Pandemic Influenza: Mexico as a Case Study. *PLoS ONE*, 4(12), e8164.
550 <https://doi.org/10.1371/journal.pone.0008164>
- 551 Clarke, K. E. N., Jones, J. M., Deng, Y., Nycz, E., Lee, A., Iachan, R., Gundlapalli, A. V., Hall, A. J., & MacNeil,
552 A. (2022). Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States,
553 September 2021–February 2022. *MMWR. Morbidity and Mortality Weekly Report*, 71(17), 606–
554 608. <https://doi.org/10.15585/mmwr.mm7117e3>
- 555 Dawood, F. S., Iuliano, A. D., Reed, C., Meltzer, M. I., Shay, D. K., Cheng, P.-Y., Bandaranayake, D.,
556 Breiman, R. F., Brooks, W. A., Buchy, P., Feikin, D. R., Fowler, K. B., Gordon, A., Hien, N. T., Horby,
557 P., Huang, Q. S., Katz, M. A., Krishnan, A., Lal, R., ... Widdowson, M.-A. (2012). Estimated global
558 mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus
559 circulation: a modelling study. *The Lancet Infectious Diseases*, 12(9), 687–695.
560 [https://doi.org/10.1016/S1473-3099\(12\)70121-4](https://doi.org/10.1016/S1473-3099(12)70121-4)
- 561 Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real
562 time. *The Lancet Infectious Diseases*, 20(5), 533–534. [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1)
- 564 Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J.
565 E., Mascola, J. R., Graham, B. S., Lin, B. C., O’Dell, S., Schmidt, S. D., Widge, A. T., Edara, V.-V.,
566 Anderson, E. J., Lai, L., Floyd, K., Roupheal, N. G., Zarnitsyna, V., ... Kunwar, P. (2021). Antibody
567 Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *New*
568 *England Journal of Medicine*, 384(23), 2259–2261. <https://doi.org/10.1056/NEJMc2103916>
- 569 Dror, A. A., Eisenbach, N., Taiber, S., Morozov, N. G., Mizrachi, M., Zigron, A., Srouji, S., & Sela, E. (2020).
570 Vaccine hesitancy: the next challenge in the fight against COVID-19. *European Journal of*
571 *Epidemiology*, 35(8), 775–779. <https://doi.org/10.1007/s10654-020-00671-y>
- 572 Duijzer, L. E., van Jaarsveld, W. L., Wallinga, J., & Dekker, R. (2018). Dose-Optimal Vaccine Allocation
573 over Multiple Populations. *Production and Operations Management*, 27(1), 143–159.
574 <https://doi.org/10.1111/poms.12788>
- 575 Emanuel, E. J., & Persad, G. (2021, May 24). This Is the Wrong Way to Distribute Badly Needed
576 Vaccines. *New York Times*. [https://www.nytimes.com/2021/05/24/opinion/vaccine-covid-](https://www.nytimes.com/2021/05/24/opinion/vaccine-covid-distribution.html)
577 [distribution.html](https://www.nytimes.com/2021/05/24/opinion/vaccine-covid-distribution.html)

- 578 European Commission. (2020). *Communication from the Commission EU Strategy for COVID-19*
579 *vaccines*. [https://ec.europa.eu/info/sites/default/files/communication-eu-strategy-vaccines-](https://ec.europa.eu/info/sites/default/files/communication-eu-strategy-vaccines-covid19_en.pdf)
580 [covid19_en.pdf](https://ec.europa.eu/info/sites/default/files/communication-eu-strategy-vaccines-covid19_en.pdf)
- 581 Fidler, D. P. (2010). Negotiating Equitable Access to Influenza Vaccines: Global Health Diplomacy and
582 the Controversies Surrounding Avian Influenza H5N1 and Pandemic Influenza H1N1. *PLoS*
583 *Medicine*, 7(5), e1000247. <https://doi.org/10.1371/journal.pmed.1000247>
- 584 Fineberg, H. V. (2014). Pandemic Preparedness and Response — Lessons from the H1N1 Influenza
585 of 2009. *New England Journal of Medicine*, 370(14), 1335–1342.
586 <https://doi.org/10.1056/NEJMra1208802>
- 587 Forster, G. A., & Gilligan, C. A. (2007). Optimizing the control of disease infestations at the landscape
588 scale. *Proceedings of the National Academy of Sciences*, 104(12), 4984–4989.
589 <https://doi.org/10.1073/pnas.0607900104>
- 590 Gayle, H., Foege, W., Brown, L., & Kahn, B. (Eds.). (2020). *Framework for Equitable Allocation of COVID-*
591 *19 Vaccine*. National Academies Press. <https://doi.org/10.17226/25917>
- 592 Goldstein, E., Lipsitch, M., & Cevik, M. (2021). On the Effect of Age on the Transmission of SARS-CoV-
593 2 in Households, Schools, and the Community. *The Journal of Infectious Diseases*, 223(3), 362–
594 369. <https://doi.org/10.1093/infdis/jiaa691>
- 595 Hogan, A. B., Winskill, P., Watson, O. J., Walker, P. G., Whittaker, C., Baguelin, M., Haw, D., Lochen, A.,
596 Gaythorpe, K. A., Team, I. C.-19 R., Muhib, F., Smith, P., Hauck, K., Ferguson, N. M., & Ghani, A. C.
597 (2020). Modelling the allocation and impact of a COVID-19 vaccine. *Imperial College London*.
598 <https://doi.org/10.25561/82822>
- 599 Islam, M. R., Oraby, T., McCombs, A., Chowdhury, M. M., Al-Mamun, M., Tyshenko, M. G., & Kadelka, C.
600 (2021). Evaluation of the United States COVID-19 vaccine allocation strategy. *PLOS ONE*, 16(11),
601 e0259700. <https://doi.org/10.1371/journal.pone.0259700>
- 602 Kaiser Family Foundation. (2009). *Nine Countries Pledge H1N1 Vaccine Donations To Developing*
603 *Countries*. [https://www.kff.org/news-summary/nine-countries-pledge-h1n1-vaccine-](https://www.kff.org/news-summary/nine-countries-pledge-h1n1-vaccine-donations-to-developing-countries/)
604 [donations-to-developing-countries/](https://www.kff.org/news-summary/nine-countries-pledge-h1n1-vaccine-donations-to-developing-countries/)
- 605 Keeling, M. J., & Shattock, A. (2012). Optimal but unequitable prophylactic distribution of vaccine.
606 *Epidemics*, 4(2), 78–85. <https://doi.org/10.1016/j.epidem.2012.03.001>
- 607 Kissler, S. M., Viboud, C., Grenfell, B. T., & Gog, J. R. (2020). Symbolic transfer entropy reveals the age
608 structure of pandemic influenza transmission from high-volume influenza-like illness data.
609 *Journal of The Royal Society Interface*, 17(164), 20190628.
610 <https://doi.org/10.1098/rsif.2019.0628>
- 611 Klepac, P., Laxminarayan, R., & Grenfell, B. T. (2011). Synthesizing epidemiological and economic
612 optima for control of immunizing infections. *Proceedings of the National Academy of Sciences*,
613 108(34), 14366–14370. <https://doi.org/10.1073/pnas.1101694108>
- 614 Ladhani, S. N., Jeffery-Smith, A., Patel, M., Janarthanan, R., Fok, J., Crawley-Boevey, E., Vusirikala, A.,
615 Fernandez Ruiz De Olano, E., Perez, M. S., Tang, S., Dun-Campbell, K., Evans, E. W., Bell, A., Patel,
616 B., Amin-Chowdhury, Z., Aiano, F., Paranthaman, K., Ma, T., Saavedra-Campos, M., ... Zambon, M.
617 (2020). High prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19:
618 Prospective cohort study, England. *EClinicalMedicine*, 28, 100597.

- 619 <https://doi.org/10.1016/j.eclinm.2020.100597>
- 620 Lee, B. Y., Brown, S. T., Korch, G. W., Cooley, P. C., Zimmerman, R. K., Wheaton, W. D., Zimmer, S. M.,
621 Grefenstette, J. J., Bailey, R. R., Assi, T.-M., & Burke, D. S. (2010). A computer simulation of vaccine
622 prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. *Vaccine*,
623 28(31), 4875–4879. <https://doi.org/10.1016/j.vaccine.2010.05.002>
- 624 Magpantay, F. M. G., Riolo, M. A., de Cellès, M. D., King, A. A., & Rohani, P. (2014). Epidemiological
625 Consequences of Imperfect Vaccines for Immunizing Infections. *SIAM Journal on Applied*
626 *Mathematics*, 74(6), 1810–1830. <https://doi.org/10.1137/140956695>
- 627 Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Rodés-Guirao, L.
628 (2021). A global database of COVID-19 vaccinations. *Nature Human Behaviour*, 5(7), 947–953.
629 <https://doi.org/10.1038/s41562-021-01122-8>
- 630 Matrajt, L., Eaton, J., Leung, T., & Brown, E. R. (2021). Vaccine optimization for COVID-19: Who to
631 vaccinate first? *Science Advances*, 7(6). <https://doi.org/10.1126/sciadv.abf1374>
- 632 Matrajt, L., & Longini, I. M. (2010). Optimizing Vaccine Allocation at Different Points in Time during
633 an Epidemic. *PLoS ONE*, 5(11), e13767. <https://doi.org/10.1371/journal.pone.0013767>
- 634 McMorrow, M. (2021). *Improving communications around vaccine breakthrough and vaccine*
635 *effectiveness.* [https://context-](https://context-cdn.washingtonpost.com/notes/prod/default/documents/8a726408-07bd-46bd-a945-3af0ae2f3c37/note/57c98604-3b54-44f0-8b44-b148d8f75165)
636 [cdn.washingtonpost.com/notes/prod/default/documents/8a726408-07bd-46bd-a945-](https://context-cdn.washingtonpost.com/notes/prod/default/documents/8a726408-07bd-46bd-a945-3af0ae2f3c37/note/57c98604-3b54-44f0-8b44-b148d8f75165)
637 [3af0ae2f3c37/note/57c98604-3b54-44f0-8b44-b148d8f75165](https://context-cdn.washingtonpost.com/notes/prod/default/documents/8a726408-07bd-46bd-a945-3af0ae2f3c37/note/57c98604-3b54-44f0-8b44-b148d8f75165)
- 638 Monod, M., Blenkinsop, A., Xi, X., Hebert, D., Bershan, S., Tietze, S., Baguelin, M., Bradley, V. C., Chen, Y.,
639 Coupland, H., Filippi, S., Ish-Horowicz, J., McManus, M., Mellan, T., Gandy, A., Hutchinson, M.,
640 Unwin, H. J. T., van Elsland, S. L., Vollmer, M. A. C., ... Ratmann, O. (2021). Age groups that sustain
641 resurging COVID-19 epidemics in the United States. *Science*, 371(6536).
642 <https://doi.org/10.1126/science.abe8372>
- 643 Moore, S., Hill, E. M., Dyson, L., Tildesley, M. J., & Keeling, M. J. (2021). Modelling optimal vaccination
644 strategy for SARS-CoV-2 in the UK. *PLOS Computational Biology*, 17(5), e1008849.
645 <https://doi.org/10.1371/journal.pcbi.1008849>
- 646 Mylius, S. D., Hagenaars, T. J., Lugner, A. K., & Wallinga, J. (2008). Optimal allocation of pandemic
647 influenza vaccine depends on age, risk and timing. *Vaccine*, 26(29–30), 3742–3749.
648 <https://doi.org/10.1016/j.vaccine.2008.04.043>
- 649 Nguyen, C., & Carlson, J. M. (2016). Optimizing Real-Time Vaccine Allocation in a Stochastic SIR Model.
650 *PLoS ONE*, 11(4), e0152950. <https://doi.org/10.1371/journal.pone.0152950>
- 651 Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín,
652 J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., Molina, M., Rodríguez-Cabrera, F.,
653 Martín, M., Merino-Amador, P., León Paniagua, J., Muñoz-Montalvo, J. F., Blanco, F., Yotti, R.,
654 Blanco, F., ... Vázquez de la Villa, A. (2020). Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a
655 nationwide, population-based seroepidemiological study. *The Lancet*, 396(10250), 535–544.
656 [https://doi.org/10.1016/S0140-6736\(20\)31483-5](https://doi.org/10.1016/S0140-6736(20)31483-5)
- 657 Presanis, A. M., De Angelis, D., Team3¶, T. N. Y. C. S. F. I., Hagy, A., Reed, C., Riley, S., Cooper, B. S., Finelli,
658 L., Biedrzycki, P., & Lipsitch, M. (2009). The Severity of Pandemic H1N1 Influenza in the United
659 States, from April to July 2009: A Bayesian Analysis. *PLOS Medicine*, 6(12), e1000207.

- 660 <https://doi.org/10.1371/journal.pmed.1000207>
- 661 Public Health England. (2020). *Sero-surveillance of COVID-19*.
662 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_d](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/888254/COVID19_Epidemiological_Summary_w22_Final.pdf)
663 [ata/file/888254/COVID19_Epidemiological_Summary_w22_Final.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/888254/COVID19_Epidemiological_Summary_w22_Final.pdf)
- 664 Rosenberg, E. S., Tesoriero, J. M., Rosenthal, E. M., Chung, R., Barranco, M. A., Styer, L. M., Parker, M.
665 M., John Leung, S.-Y., Morne, J. E., Greene, D., Holtgrave, D. R., Hoefler, D., Kumar, J., Udo, T., Hutton,
666 B., & Zucker, H. A. (2020). Cumulative incidence and diagnosis of SARS-CoV-2 infection in New
667 York. *Annals of Epidemiology*, 48, 23-29.e4. <https://doi.org/10.1016/j.annepidem.2020.06.004>
- 668 Rowthorn, R. E., Laxminarayan, R., & Gilligan, C. A. (2009). Optimal control of epidemics in
669 metapopulations. *Journal of The Royal Society Interface*, 6(41), 1135–1144.
670 <https://doi.org/10.1098/rsif.2008.0402>
- 671 Rydland, H. T., Friedman, J., Stringhini, S., Link, B. G., & Eikemo, T. A. (2022). The radically unequal
672 distribution of Covid-19 vaccinations: a predictable yet avoidable symptom of the fundamental
673 causes of inequality. *Humanities and Social Sciences Communications*, 9(1), 61.
674 <https://doi.org/10.1057/s41599-022-01073-z>
- 675 Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N.,
676 Richet, J., Dubost, C.-L., Le Strat, Y., Lessler, J., Levy-Bruhl, D., Fontanet, A., Opatowski, L., Boelle,
677 P.-Y., & Cauchemez, S. (2020). Estimating the burden of SARS-CoV-2 in France. *Science*,
678 369(6500), 208–211. <https://doi.org/10.1126/science.abc3517>
- 679 Simonsen, L., Spreeuwenberg, P., Lustig, R., Taylor, R. J., Fleming, D. M., Kroneman, M., Van Kerkhove,
680 M. D., Mounts, A. W., & Paget, W. J. (2013). Global Mortality Estimates for the 2009 Influenza
681 Pandemic from the GLaMOR Project: A Modeling Study. *PLoS Medicine*, 10(11), e1001558.
682 <https://doi.org/10.1371/journal.pmed.1001558>
- 683 Teytelman, A., & Larson, R. C. (2013). Multiregional Dynamic Vaccine Allocation During an Influenza
684 Epidemic. *Service Science*, 5(3), 197–215. <https://doi.org/10.1287/serv.2013.0046>
- 685 Tuite, A. R., Fisman, D. N., Kwong, J. C., & Greer, A. L. (2010). Optimal Pandemic Influenza Vaccine
686 Allocation Strategies for the Canadian Population. *PLoS ONE*, 5(5), e10520.
687 <https://doi.org/10.1371/journal.pone.0010520>
- 688 Watson, O. J., Barnsley, G., Toor, J., Hogan, A. B., Winskill, P., & Ghani, A. C. (2022). Global impact of the
689 first year of COVID-19 vaccination: a mathematical modelling study. *The Lancet Infectious*
690 *Diseases*. [https://doi.org/10.1016/S1473-3099\(22\)00320-6](https://doi.org/10.1016/S1473-3099(22)00320-6)
- 691 Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar,
692 A., Evans, D., Inglesby, P., Cockburn, J., McDonald, H. I., MacKenna, B., Tomlinson, L., Douglas, I.
693 J., Rentsch, C. T., Mathur, R., Wong, A. Y. S., Grieve, R., ... Goldacre, B. (2020). Factors associated
694 with COVID-19-related death using OpenSAFELY. *Nature*, 584(7821), 430–436.
695 <https://doi.org/10.1038/s41586-020-2521-4>
- 696 World Health Organization. (2011). *Pandemic influenza preparedness Framework for the sharing of*
697 *influenza viruses and access to vaccines and other benefits*.
698 https://apps.who.int/gb/pip/pdf_files/pandemic-influenza-preparedness-en.pdf
- 699 World Health Organization. (2020). *WHO Concept for fair access and equitable allocation of COVID19*
700 *health products*. <https://www.who.int/docs/default-source/coronaviruse/who-covid19->

- 701 vaccine-allocation-final-working-version-9sept.pdf
- 702 Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., Song, J.,
703 Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, X., Chen, D., Xiong, W., ... Song, Y. (2020). Risk Factors
704 Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus
705 Disease 2019 Pneumonia in Wuhan, China. *JAMA Internal Medicine*, *180*(7), 934.
706 <https://doi.org/10.1001/jamainternmed.2020.0994>
- 707 Wu, J. T., Riley, S., & Leung, G. M. (2007). Spatial considerations for the allocation of pre-pandemic
708 influenza vaccination in the United States. *Proceedings of the Royal Society B: Biological Sciences*,
709 *274*(1627), 2811–2817. <https://doi.org/10.1098/rspb.2007.0893>
- 710 Yuan, E. C., Alderson, D. L., Stromberg, S., & Carlson, J. M. (2015). Optimal Vaccination in a Stochastic
711 Epidemic Model of Two Non-Interacting Populations. *PLOS ONE*, *10*(2), e0115826.
712 <https://doi.org/10.1371/journal.pone.0115826>
- 713 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., Guan, L., Wei, Y., Li, H.,
714 Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H., & Cao, B. (2020). Clinical course and risk factors for
715 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The*
716 *Lancet*, *395*(10229), 1054–1062. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
- 717